Plains GP Holdings (PAGP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
Board recommends voting FOR Proposal 3, the advisory vote to approve 2025 named executive officer compensation, at the 2026 annual meetings.
ISS recommended voting against Proposal 3, while Glass Lewis recommended voting for it.
Board disagrees with ISS's concerns and provides detailed responses to each point.
Voting matters and shareholder proposals
Proposal 3 seeks shareholder approval of 2025 named executive officer compensation on an advisory basis.
Board urges shareholders and unitholders to vote FOR Proposal 3 at the 2026 annual meetings.
Board of directors and corporate governance
Board approved extension of CEO's 2018 Promotional Grant to retain the CEO for up to five additional years and support succession planning.
Extension intended to ensure stability and continued execution of key strategic initiatives.
Latest events from Plains GP Holdings
- Cynthia B. Taylor joins as an independent director, enhancing board expertise and ESG oversight.PAGP
Proxy filing13 May 2026 - Sector-leading yield, efficient growth, and robust cash flow drive multi-year distribution growth.PAGP
Investor presentation11 May 2026 - 2026 EBITDA guidance raised to $2.88B as NGL sale proceeds target debt reduction.PAGP
Q1 202611 May 2026 - 2025 saw $2.83B EBITDA, higher distributions, and a strategic NGL exit with strong 2026 outlook.PAGP
Q4 202513 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and major 2025 strategic actions.PAGP
Proxy filing10 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.PAGP
Proxy filing10 Apr 2026 - Shelf registration allows flexible sale of up to $938.9M in Class A shares for midstream investment.PAGP
Registration filing30 Mar 2026 - Exceeded guidance, raised distributions, and forecasted growth driven by acquisitions and Permian strength.PAGP
Q4 20249 Feb 2026 - Q2 2024 Adjusted EBITDA beat expectations; full-year guidance raised on strong execution.PAGP
Q2 20249 Feb 2026